What is the price-to-earnings ratio of Zomedica?
The price-earnings ratio of Zomedica is currently 4.65.
Zomedica P/S 2024
Zomedica P/S
4.65
Ticker
ZOM
ISIN
CA98980M1095
WKN
A2QEF3
As of Sep 18, 2024, Zomedica's P/S ratio stood at 4.65, a -39.92% change from the 7.74 P/S ratio recorded in the previous year.
The Zomedica P/S history
Zomedica Aktienanalyse
What does Zomedica do?
Zomedica Corp is an emerging company specializing in the development and marketing of innovative diagnostics and treatment options for pets. The company was founded in 2015 and is headquartered in Ann Arbor, Michigan. Zomedica's business model is primarily focused on providing better diagnostics and therapy for pets to veterinarians and pet owners. The company develops and markets veterinary diagnostics and precise treatment solutions for various diseases in pets. Zomedica is divided into different divisions specializing in different areas of veterinary diagnostics and therapy. One of these divisions is "Point-of-Care" diagnostics, which allows veterinarians to perform quick and accurate diagnoses directly in their practice. Zomedica offers innovative devices and tests for the rapid diagnosis of diseases such as prostatitis or hypothyroidism. Another important division is "Companion Diagnostic" diagnostics, which is specifically focused on the diagnosis of cancer in pets. Zomedica has developed innovative tests that enable quick and precise diagnoses, allowing for targeted therapy initiation. In addition to diagnostics, Zomedica also offers innovative therapy solutions for pets. The company focuses on the development of antibiotics for animals, as well as precise treatment solutions for diseases such as diabetes or chronic kidney disease. One of Zomedica's best-known products is TRUFORMA, an innovative diagnostic device for veterinarians that enables quick and precise diagnosis of various diseases. The company has also developed a range of tests for the diagnosis of thyroid disease, prostatitis, and diabetes. In recent years, Zomedica has become one of the leading companies in veterinary diagnostics and therapy and has already convinced numerous veterinarians and pet owners of its innovative products and solutions. The company relies on close collaboration with veterinarians to continuously improve its products and tailor them to the needs of the market. Overall, Zomedica is an innovative company specializing in products and solutions for the needs of veterinarians and pet owners. With its innovative diagnostics and treatment solutions, the company is setting new standards in veterinary medicine and contributing to the improvement of pet health worldwide. Zomedica ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Zomedica's P/S Ratio
Zomedica's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Zomedica's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Zomedica's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Zomedica’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Zomedica stock
How has the price-earnings ratio of Zomedica changed compared to last year?
The price-to-earnings ratio of Zomedica has increased by -39.92% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Zomedica high compared to other companies?
Yes, the price-to-earnings ratio of Zomedica is high compared to other companies.
How does an increase in the price-earnings ratio of Zomedica affect the company?
An increase in the price-earnings ratio of Zomedica would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Zomedica affect the company?
A decrease in the price-earnings ratio of Zomedica would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Zomedica?
Some factors that influence the price-earnings ratio of Zomedica are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Zomedica pay?
Over the past 12 months, Zomedica paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zomedica is expected to pay a dividend of 0 USD.
What is the dividend yield of Zomedica?
The current dividend yield of Zomedica is .
When does Zomedica pay dividends?
Zomedica pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Zomedica?
Zomedica paid dividends every year for the past 0 years.
What is the dividend of Zomedica?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Zomedica located?
Zomedica is assigned to the 'Health' sector.
Wann musste ich die Aktien von Zomedica kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Zomedica from 9/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/18/2024.
When did Zomedica pay the last dividend?
The last dividend was paid out on 9/18/2024.
What was the dividend of Zomedica in the year 2023?
In the year 2023, Zomedica distributed 0 USD as dividends.
In which currency does Zomedica pay out the dividend?
The dividends of Zomedica are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Zomedica
Our stock analysis for Zomedica Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zomedica Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
